Acute Kidney Injury, Chronic Kidney Diseases
Conditions
Keywords
eGFR, Creatinine, POCT
Brief summary
To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (the Siemens EXL creatinine determination). To assess the Ease of Use of the Nova Max Creatinine and eGFR Meter System in the hands of the intended CLIA-Waived Point-of-Care users.
Detailed description
This study is designed to evaluate the performance of the NM Meter when used by CLIAW operators in terms of both accuracy to an established reference method and precision. CLIAW operators will receive no training or prompting on how to use the NM Creatinine and eGFR Meter, operating only using the instructions found in printed labeling materials (IFU, QRG, packaging). In determining the accuracy of the device, subjects will be tested using the NM Creatinine and eGFR Meter alongside a central laboratory reference method and the results will be compared to one another. This portion of the study is referred to as Method Comparison. In determining the precision of the device, multiple creatinine determinations will be made with the NM Creatinine and eGFR meter using both stabilized control materials (testing over the course of 20 days) and venous whole blood specimens (tested over the course of a single day). The difference between the multiple test results will determine the device's level of precision. This portion of the study is referred to as Precision.
Interventions
DIAGNOSTIC_TESTCreatinine, eGFR
Compare diagnostic tests to reference methods
Sponsors
South Florida Research Organization
Charisma Medical and Research Center
Excellence Medical Research
Nova Biomedical
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult males or females (≥ 18 years of age) 2. CKD Stage 1 (healthy) 3. CKD Stages 2-4 4. Subjects willing and able to consent to participating in the study. 5. Subjects whose pre-screen creatinine and eGFR value, if performed, is deemed valuable to the study.
Exclusion criteria
1. Subjects unable to consent to participating in the study. 2. Subjects possessing a cognitive disorder or other condition, which, in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analytical verification of Nova Max creatinine and eGFR meter system - Creatinine comparison | 20 days | Nova Max creatinine and eGFR meter system, a point of care testing instrument is as effective as a reference laboratory method for Creatinine blood results in mg/dL |
| Analytical verification of Nova Max creatinine and eGFR meter system - eGFR comparison | 20 days | Nova Max creatinine and eGFR meter system, a point of care testing instrument is as effective as a reference laboratory method for eGFR blood results in mL/min/1.73 m\^2 |
Countries
United States
Outcome results
None listed